Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, reported a net loss of $10.6 million, or $0.05 per share ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE